These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1125 related items for PubMed ID: 26111104

  • 1. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
    von Minckwitz G, Conrad B, Reimer T, Decker T, Eidtmann H, Eiermann W, Hackmann J, Möbus V, Marmé F, Potenberg J, Stickeler E, Simon E, Thomssen C, Huober J, Denkert C, Alfer J, Jackisch C, Nekljudova V, Burchardi N, Loibl S, German Breast Group Investigators.
    Cancer; 2015 Oct 15; 121(20):3639-48. PubMed ID: 26111104
    [Abstract] [Full Text] [Related]

  • 2. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
    Cameron D, Morden JP, Canney P, Velikova G, Coleman R, Bartlett J, Agrawal R, Banerji J, Bertelli G, Bloomfield D, Brunt AM, Earl H, Ellis P, Gaunt C, Gillman A, Hearfield N, Laing R, Murray N, Couper N, Stein RC, Verrill M, Wardley A, Barrett-Lee P, Bliss JM, TACT2 Investigators.
    Lancet Oncol; 2017 Jul 15; 18(7):929-945. PubMed ID: 28600210
    [Abstract] [Full Text] [Related]

  • 3. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
    Martín M, Ruiz Simón A, Ruiz Borrego M, Ribelles N, Rodríguez-Lescure Á, Muñoz-Mateu M, González S, Margelí Vila M, Barnadas A, Ramos M, Del Barco Berron S, Jara C, Calvo L, Martínez-Jáñez N, Mendiola Fernández C, Rodríguez CA, Martínez de Dueñas E, Andrés R, Plazaola A, de la Haba-Rodríguez J, López-Vega JM, Adrover E, Ballesteros AI, Santaballa A, Sánchez-Rovira P, Baena-Cañada JM, Casas M, del Carmen Cámara M, Carrasco EM, Lluch A.
    J Clin Oncol; 2015 Nov 10; 33(32):3788-95. PubMed ID: 26416999
    [Abstract] [Full Text] [Related]

  • 4. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgery.
    Untch M, Fasching PA, Konecny GE, von Koch F, Conrad U, Fett W, Kurzeder C, Lück HJ, Stickeler E, Urbaczyk H, Liedtke B, Salat C, Harbeck N, Müller V, Schmidt M, Hasmüller S, Lenhard M, Schuster T, Nekljudova V, Lebeau A, Loibl S, von Minckwitz G, Arbeitsgemeinschaft Gynäkologische Onkologie PREPARE investigators.
    Ann Oncol; 2011 Sep 10; 22(9):1988-1998. PubMed ID: 21385882
    [Abstract] [Full Text] [Related]

  • 5. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
    Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Durando A, Turletti A, Nisticò C, Valle E, Garrone O, Puglisi F, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Giuliano M, Gravina A, Papaldo P, Bighin C, Bisagni G, Forestieri V, Cognetti F, Gruppo Italiano Mammella (GIM) investigators.
    Lancet; 2015 May 09; 385(9980):1863-72. PubMed ID: 25740286
    [Abstract] [Full Text] [Related]

  • 6. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosis.
    Untch M, von Minckwitz G, Konecny GE, Conrad U, Fett W, Kurzeder C, Lück HJ, Stickeler E, Urbaczyk H, Liedtke B, Beckmann MW, Salat C, Harbeck N, Müller V, Schmidt M, Hasmüller S, Lenhard M, Nekljudova V, Lebeau A, Loibl S, Fasching PA, Arbeitsgemeinschaft Gynäkologische Onkologie PREPARE investigators.
    Ann Oncol; 2011 Sep 09; 22(9):1999-2006. PubMed ID: 21382868
    [Abstract] [Full Text] [Related]

  • 7. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial.
    Velikova G, Morden JP, Haviland JS, Emery C, Barrett-Lee P, Earl H, Bloomfield D, Brunt AM, Canney P, Coleman R, Verrill M, Wardley A, Bertelli G, Ellis P, Stein R, Bliss JM, Cameron D, TACT2 Trial Management Group.
    Lancet Oncol; 2023 Dec 09; 24(12):1359-1374. PubMed ID: 37926100
    [Abstract] [Full Text] [Related]

  • 8. Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer.
    Boccardo F, Amadori D, Guglielmini P, Sismondi P, Farris A, Agostara B, Gambi A, Catalano G, Faedi M, Rubagotti A.
    Oncology; 2010 Dec 09; 78(3-4):274-81. PubMed ID: 20530973
    [Abstract] [Full Text] [Related]

  • 9. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
    Ackland SP, Anton A, Breitbach GP, Colajori E, Tursi JM, Delfino C, Efremidis A, Ezzat A, Fittipaldo A, Kolaric K, Lopez M, Viaro D, HEPI 013 study group.
    J Clin Oncol; 2001 Feb 15; 19(4):943-53. PubMed ID: 11181656
    [Abstract] [Full Text] [Related]

  • 10. Neoadjuvant chemotherapy for breast cancer with weekly nab-paclitaxel followed by epirubicin and cyclophosphamide--results of a case series.
    Hahn A, Schlotter CM, Rossmanith WG, Ulmer HU, Staiger HJ, Villena C.
    In Vivo; 2014 Feb 15; 28(2):235-41. PubMed ID: 24632979
    [Abstract] [Full Text] [Related]

  • 11. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
    Cocconi G, Di Blasio B, Boni C, Bisagni G, Ceci G, Rondini E, Bella M, Leonardi F, Savoldi L, Camisa R, Bruzzi P.
    Cancer; 2002 Jul 15; 95(2):228-35. PubMed ID: 12124820
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer.
    Robidoux A, Buzdar AU, Quinaux E, Jacobs S, Rastogi P, Fourchotte V, Younan RJ, Pajon ER, Shalaby IA, Desai AM, Fehrenbacher L, Geyer CE, Mamounas EP, Wolmark N.
    Clin Breast Cancer; 2010 Feb 15; 10(1):81-6. PubMed ID: 20133263
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93) - the German Adjuvant Breast Cancer Group.
    Eiermann W, Graf E, Ataseven B, Conrad B, Hilfrich J, Massinger-Biebl H, Vescia S, Loibl S, von Minckwitz G, Schumacher M, Kaufmann M, German Adjuvant Breast Cancer Group.
    Eur J Cancer; 2010 Jan 15; 46(1):84-94. PubMed ID: 19879750
    [Abstract] [Full Text] [Related]

  • 16. Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy.
    de Azambuja E, Ameye L, Diaz M, Vandenbossche S, Aftimos P, Bejarano Hernández S, Shih-Li C, Delhaye F, Focan C, Cornez N, Vindevoghel A, Beauduin M, Lemort M, Paesmans M, Suter T, Piccart-Gebhart M.
    Eur J Cancer; 2015 Nov 15; 51(17):2517-24. PubMed ID: 26321502
    [Abstract] [Full Text] [Related]

  • 17. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
    Yardley D, Burris H, Peacock N, Raefsky E, Melnik M, Inhorn R, Shipley D, Hainsworth J.
    Breast Cancer Res Treat; 2010 Sep 15; 123(2):471-5. PubMed ID: 20658263
    [Abstract] [Full Text] [Related]

  • 18. Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes.
    Battelli N, Massacesi C, Braconi C, Pilone A, Manzione L, Dinota A, Cobelli S, Scanni A, Sturba F, Giacomini G, Morale D, Giorgi F, Tummarello D, Cascinu S.
    Am J Clin Oncol; 2006 Aug 15; 29(4):380-4. PubMed ID: 16891866
    [Abstract] [Full Text] [Related]

  • 19. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.
    Poole CJ, Earl HM, Hiller L, Dunn JA, Bathers S, Grieve RJ, Spooner DA, Agrawal RK, Fernando IN, Brunt AM, O'Reilly SM, Crawford SM, Rea DW, Simmonds P, Mansi JL, Stanley A, Harvey P, McAdam K, Foster L, Leonard RC, Twelves CJ, NEAT Investigators and the SCTBG.
    N Engl J Med; 2006 Nov 02; 355(18):1851-62. PubMed ID: 17079759
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.